A solid progress update, although it doesn’t contain many surprises. Certainly another de-risked step on the way to Colostat as a marketable product. There’s little trade volume and one has to wonder what it’s going to take to bring the share price back above the ipo of .20. Seems very undervalued considering the milestones that have been achieved. A good result from Study 6 (Q1 2029?) will undoubtably make this company worth a lot of money.
